摘要
目前，化疗是胶质瘤治疗的重要环节，但化疗耐药严重影响了临床效果。肿瘤耐药机制复杂，与肿瘤细胞内耐药基因作用、多药耐药性（MDR）、脑肿瘤干细胞（BTSC）的增殖、DNA损伤修复能力异常等有关。现就脑胶质瘤耐药机制的研究进展情况综述如下。
出处
《山东医药》
CAS
北大核心
2011年第2期111-112,共2页
Shandong Medical Journal
参考文献12
-
1Faria GP, Oliveira JA, Oliveim JG, et al. Differences in the expression pattern of P-glycoprotein and MRP1 in low-grade and high- grade gliomas[ J]. Cancer Invest,2008,26(9) :883-889.
-
2Valera ET, Brassesco MS, Jabado N, et al. Pediatric glioblastoma cell line shows different patterns of expression of transmembrane ABC transporters after in vitro exposure to vinblastine [ J ]. Childs Nerv Syst,2009,25( 1 ) :39-45.
-
3Schaich M,Kestel L,Pfirrmann M ,et al. A MDR1 (ABCBI) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients[J]. Ann Oncol,2009 ,20( 1 ) :175-181.
-
4Calatozzolo C, Gelati M, Ciusani E, et al. Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 AND GST-πin humanglioma[ J]. J Neuroonco1,2005,74(2) : 113-121.
-
5Valera ET, Lucio-Eterovie AK, Neder L, et al. Quantitative PCR analysis of the expression profile of genes related to multiple drug resistance in tumors of the central nervous system[J].J Neurooncol, 2007,85 ( 1 ) : 1-10.
-
6Ezer R, Monso I, Perira E, et al. Identification of glutathione Stransferase polymorphisms in brain tumors and association with susceptibility to pediatric astrocytomas [ J ]. J Neurooncol, 2002,59 (2) :123.
-
7Fruehauf JP, Brem H, Sloan A, et al. In vitro drug response and molecular markers associated with drug resistance in malignant gliomas [ J ]. Clin Cancer Res ,2006,12 ( 15 ) :4523-4532.
-
8Platet N, Mayo J, Berger F, et al. luctuation of the SP/non-SP phenotype in the C6 glioma cell line [ J ]. FEBS Lett, 2007,581 (7) : 1435-1440.
-
9Blough MD, Zlatescu MC, Cairncmss JG, et al. O6-methylguanine- DNA methyltransferase regulation by p53 in astrocytic cells [ J ]. Cancer Res,2007,67(2) :580-584.
-
10Rodriguez FJ,Thibodeau SN,Jenkin RB,et al. MGMT immunohistochemical expression and promoter methylation in human glioblastoma [ J ]. Appl Immunohistochem Mol Morphol, 2008,16 ( 1 ) :59-65.
共引文献4
-
1邵翠杰,史泓浏,陈忠平.胶质瘤耐药的分子机制[J].中国肿瘤,2006,15(3):163-167. 被引量：7
-
2凌海慧,周燕萍,刘军.肿瘤多药耐药机制研究进展[J].国际生物医学工程杂志,2012,35(1):57-60. 被引量：1
-
3黎小妍,张二红,刘玉兴,张平.肿瘤多药耐药机制及其逆转方案的研究[J].中国处方药,2012,10(4):24-27. 被引量：4
-
4张宏鑫,张颖.食管癌多药耐药机制的研究进展[J].现代药物与临床,2015,30(6):742-746. 被引量：7
同被引文献86
-
1邵泽勇,沈鼎明,伍烽,翟宝进,王智彪.两种方法建立的人肝癌细胞多药耐药模型的比较[J].肿瘤,2005,25(1):51-54. 被引量：4
-
2邓永文,方加胜,李茗初,陈风华,周向阳,伍军,周仁辉,方芳,陈成,卢明,曾飞跃.脑肿瘤干细胞与神经上皮肿瘤病理级别的相关性[J].中南大学学报（医学版）,2006,31(1):45-51. 被引量：6
-
3Jin-rong FU,Wen-li LIU,Jian-feng ZHOU,Han-ying SUN,Hui-zhen XU,Li LUO,Heng ZHANG,Yu-feng ZHOU.Sonic hedgehog protein promotes bone marrow-derived endothelial pro-genitor cell proliferation,migration and VEGF production via PI 3-kinase/Akt signaling pathways[J].Acta Pharmacologica Sinica,2006,27(6):685-693. 被引量：7
-
4Clement V Sanchez P de Tribolet N Radovanovic I Ruiz i Altaba A.HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity[J].中国神经肿瘤杂志,2007,5(2):122-122. 被引量：97
-
5Reya T,Morrison SJ,Clarke MF,et al. Stem cells,cancer,and cancer stem cells. Nature,2001,414 : 105-111.
-
6Fargeas CA, Huttner WB, Corbeil D. Nomenclature of prominin-1 ( CD133 ) splice variants-an update. Tissue Antigens, 2007,69 : 602-606.
-
7Kemper K,Sprick MR, de Bree M, et al. The AC133 epitope,but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res ,2010,70:719-729.
-
8Shmelkov SV, St Clair R, Lyden D, et al. AC133/CD133/Prominin-1. Int J Biochem Cell Biol,2005,37:715-719.
-
9Uchida N, Buck DW, He D, et al. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci U S A, 2000,97 : 14720-14725.
-
10Richardson GD, Robson CN, Lang SH, et al. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci, 2004, 117:3539-3545.
引证文献5
-
1王欣欣,刘季平.脑肿瘤干细胞的研究现状[J].中国组织工程研究,2012,16(14):2637-2640. 被引量：4
-
2曾令成,万锋,韩林,雷霆.CD133：脑胶质瘤干细胞标志物？[J].中华神经外科杂志,2012,28(7):744-747. 被引量：1
-
3向定朝,王存祖,陆晓峰,欧阳琦.大剂量冲击法建立胶质瘤耐替莫唑胺细胞株及生物学鉴定[J].江苏大学学报（医学版）,2013,23(1):22-25. 被引量：1
-
4汪宇,丁建军.脑胶质瘤干细胞Hedgehog信号通路研究进展[J].中国临床神经外科杂志,2014,19(12):763-765.
-
5苗锐,赵耀,杨荣军,高兴春,郭娜.紫草素对人脑胶质瘤U251细胞增殖和凋亡的影响[J].现代生物医学进展,2016,16(19):3646-3649. 被引量：5
二级引证文献11
-
1赵中甫,樊锐太,杨永,孙剑瑞,胡祥,Eileen Shen,杨波.脑胶质瘤中肿瘤干细胞的体外放射敏感性[J].中国组织工程研究,2013,17(19):3455-3460. 被引量：1
-
2黄从刚,郭振涛,陈谦学,卞红强,段栩飞,李正伟,周利华,马钊.胶质瘤U251耐替莫唑胺细胞株放射照射后细胞周期及P-糖蛋白表达变化[J].中华实验外科杂志,2014,31(9):1883-1885. 被引量：4
-
3姚先进,栾佐,杨印祥,汪兆艳.人胎脑源性神经前体细胞致瘤性评价[J].现代生物医学进展,2014,14(31):6028-6031.
-
4汪宇,丁建军.脑胶质瘤干细胞Hedgehog信号通路研究进展[J].中国临床神经外科杂志,2014,19(12):763-765.
-
5Jian-jun Sun,Zhen-yu Wang,Ling-song Li,Hai-yan Yu,Yong-sheng Xu,Hai-bo Wu,Yi Luo,Bin Liu,Mei Zheng,Jin-long Mao,Xiao-hui Lou.Prevention against diffuse spinal cord astrocytoma: can the Notch pathway be a novel treatment target?[J].Neural Regeneration Research,2015,10(2):244-251. 被引量：1
-
6赵一清,欧阳陶辉,曾令成,于加省,陈坚,雷霆.脑胶质母细胞瘤干细胞球中标记滞留细胞表型研究[J].中华神经外科杂志,2015,31(8):828-834.
-
7赵亮,彭洪兴,张丽,卞婉莹,梁永.五味子乙素和γ-分泌酶抑制剂GSI联用对脑胶质瘤细胞增殖和凋亡的影响及其机制研究[J].肿瘤药学,2017,7(3):290-295. 被引量：1
-
8刘晓莉,姚草原,熊弢.紫草素对人非小细胞肺癌A549细胞增殖与凋亡的影响[J].临床和实验医学杂志,2019,18(19):2052-2056. 被引量：14
-
9张旭,田召辉,郭琳,娄永利.土木香内酯对人胶质瘤U251细胞增殖、凋亡的影响[J].中国临床神经外科杂志,2020,25(1):32-35.
-
10叶禾,张智,郑佳状,汪凡栋,陈宇,宋昭君,刘元彬,廖伟,唐龙.紫草素对椎间盘髓核细胞凋亡的影响[J].西部医学,2020,32(4):500-504. 被引量：5
-
1邓红艳.谷胱甘肽—S—转移酶与肿瘤耐药机制的探讨[J].中国医药情报,1999,5(2):75-76. 被引量：5
-
2梁华茂.卵巢癌顺铂耐药的分子机制研究进展[J].国外医学（妇产科学分册）,2001,28(4):220-222. 被引量：2
-
3王鑫,王洁,张燕,高志光.肿瘤细胞耐药机制的研究进展[J].癌症进展,2007,5(1):73-78. 被引量：2
-
4杜芹,杨锡贵.肿瘤耐药机制及其逆转措施的研究[J].实用癌症杂志,2008,23(4):427-429. 被引量：9
-
5张倩,周晓伟,王焱,孙建方.黑素瘤发病机制相关蛋白的研究进展[J].国际皮肤性病学杂志,2016,42(1):46-49.
-
6陈珣,孙红.卵巢癌化疗耐药与染色体[J].国外医学（计划生育分册）,2005,24(3):154-157.
-
7秦岭,纪春岩.肿瘤耐药机制及RNA干扰技术在逆转肿瘤耐药中的应用[J].山东医药,2006,46(30):80-81. 被引量：2
-
8郭威,宋光,吴国新.消化道恶性肿瘤多药耐药的临床研究[J].中国基层医药,2006,13(11):1862-1863.
-
9王兴,姜真,孙长岗.乙醛脱氢酶1与乳腺癌耐药蛋白在乳腺癌中的表达及相关性研究[J].中国癌症杂志,2014,24(3):175-181. 被引量：5
-
10杨纯正,许元富,齐静.应重视肿瘤耐药机制和耐药基因检测研究及应用[J].中华检验医学杂志,2005,28(12):1221-1224. 被引量：6
